comparemela.com

Latest Breaking News On - Erin hare - Page 1 : comparemela.com

Raymond Doskocil, age 79, died Friday, November 24, 2023

Raymond Doskocil, age 79, died Friday, November 24, 2023
tdtnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tdtnews.com Daily Mail and Mail on Sunday newspapers.

Blood test for kidney rejection suggests new way to treat post-transplant patients

 E-Mail IMAGE: Pittsburgh Steelers Chair in Transplantation and professor of surgery, medicine and immunology, University of Pittsburgh School of Medicine view more  Credit: Thomas E. Starzl Transplantation Institute at the University of Pittsburgh PITTSBURGH, Feb. 24, 2021 - Researchers at the University of Pittsburgh School of Medicine have discovered a blood biomarker that predicts kidney transplant rejection with a lead time of about eight months, which could give doctors an opportunity to intervene and prevent permanent damage. These results, published today in Science Translational Medicine, not only identify a warning signal that something is going wrong, but also suggest an existing medication that could be given to these patients to right the course of their long-term recovery.

The original antigenic sin: How childhood infections could shape pandemics

 E-Mail Credit: UPMC PITTSBURGH, Feb. 18, 2021 - A child s first influenza infection shapes their immunity to future airborne flu viruses including emerging pandemic strains. But not all flu strains spur the same initial immune defense, according to new findings published today by University of Pittsburgh School of Medicine virologists in the journal PLOS Pathogens. These results are relevant right now to the COVID-19 pandemic, said senior author Seema Lakdawala, Ph.D., assistant professor of microbiology and molecular genetics at Pitt. They may explain age-based distributions of SARS-CoV-2 disease severity and susceptibility. Having flu once does not make you immune to all future influenza viruses, she said. Nor does having had the original SARS virus in 2003 or any of the common cold coronaviruses in circulation necessarily mean you can t get infected with SARS-CoV-2. But your susceptibility to infection might be different than someone who has never encountered a co

Cheap, potent pathway to pandemic therapeutics

Loading video. VIDEO: A diverse collections of simulated nanobodies bind to different parts of a protein antigen. view more  Credit: Zhe Sang PITTSBURGH, Feb. 15, 2021 - By capitalizing on a convergence of chemical, biological and artificial intelligence advances, University of Pittsburgh School of Medicine scientists have developed an unusually fast and efficient method for discovering tiny antibody fragments with big potential for development into therapeutics against deadly diseases. The technique, published today in the journal Cell Systems, is the same process the Pitt team used to extract tiny SARS-CoV-2 antibody fragments from llamas, which could become an inhalable COVID-19 treatment for humans. This approach has the potential to quickly identify multiple potent nanobodies that target different parts of a pathogen thwarting variants.

Fecal transplant turns cancer immunotherapy non-responders into responders

Credit: UPMC PITTSBURGH, Feb. 4, 2021 - Researchers at UPMC Hillman Cancer Center and the National Cancer Institute (NCI) demonstrate that changing the gut microbiome can transform patients with advanced melanoma who never responded to immunotherapy which has a failure rate of 40% for this type of cancer into patients who do. The results of this proof-of-principle phase II clinical trial were published online today in Science. In this study, a team of researchers from UPMC Hillman administered fecal microbiota transplants (FMT) and anti-PD-1 immunotherapy to melanoma patients who had failed all available therapies, including anti-PD-1, and then tracked clinical and immunological outcomes. Collaborators at NCI analyzed microbiome samples from these patients to understand why FMT seems to boost their response to immunotherapy.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.